TPP1 and CLN2 disease: So as to develop a treatment of the brain in CLN2 disease, the TPP1 proenzyme was infused in children with CLN2 disease into a lateral ventricle with a chronically implanted Ommaya reservoir every 2 weeks at a dose of 300 mg of enzyme in a volume of 10 mL over a 4 h period [110].